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Idiopathic non-cirrhotic portal hypertension (INCPH) is a rare disease characterized of intrahepatic portal hypertension
in the absence of cirrhosis or other causes of liver disease and splanchnic venous thrombosis. The etiology of
INCPH can be classified in five categories: 1) immunological disorders (i.e. association with common variable
immunodeficiency syndrome, connective tissue diseases, Crohn’s disease, etc.), 2) chronic infections, 3) exposure to
medications or toxins (e.g. azathioprine, 6- thioguanine, arsenic), 4) genetic predisposition (i.e. familial aggregation
and association with Adams-Oliver syndrome and Turner disease) and 5) prothrombotic conditions (e.g. inherited
thrombophilias myeloproliferative neoplasm antiphospholipid syndrome). Roughly, INCPH diagnosis is based on
clinical criteria and the formal exclusion of any other causes of portal hypertension. A formal diagnosis is based
on the following criteria: 1) presence of unequivocal signs of portal hypertension, 2) absence of cirrhosis, advanced
fibrosis or other causes of chronic liver diseases, and 3) absence of thrombosis of the hepatic veins or of the portal
vein at imaging. Patients with INCPH usually present with signs or symptoms of portal hypertension such as
gastro-esophageal varices, variceal bleeding or splenomegaly. Ascites and/or liver failure can occur in the context
of precipitating factors. The development of portal vein thrombosis is common. Survival is manly limited by
concomitant disorders. Currently, treatment of INCPH relies on the prevention of complications related to portal
hypertension, following current guidelines of cirrhotic portal hypertension. No treatment has been studied aimed
to modify the natural history of the disease. Anticoagulation therapy can be considered in patients who develop
portal vein thrombosis.
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Idiopathic non-cirrhotic portal hypertension (INCPH) is a
rare disease characterized by of intrahepatic portal hyper-
tension in the absence of cirrhosis, other causes of liver dis-
ease and splanchnic venous thrombosis [1–7]. Histological
features of INCPH comprise a wide spectrum of nonspe-
cific features, ranging from minor changes, sinusoidal dila-
tation, phlebosclerosis and portal fibrosis to nodular
regenerative hyperplasia. It is still unclear whether this rep-
ertoire of histological changes reflects different stages of the
disease, or it could also be that INCPH comprises different
nosologic entities that share the same clinical presentation.
Different conditions have been associated to this disorder
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creativecommons.org/publicdomain/zero/1.0/HIV infection and antiretroviral treatment, trace metals,
certain medications and prothrombotic factors [1, 3, 7–9].
The pathophysiological mechanisms causing INCPH re-
main largely unknown. Patients with INCPH usually
present with signs and symptoms of portal hypertension
(PH) such as splenomegaly, thrombocytopenia and vari-
ceal bleeding [1, 2, 5]. Patients can develop additional
liver-related complications such as ascites, hepatic en-
cephalopathy, portal vein thrombosis (PVT) or liver fail-
ure, that could eventually require liver transplantation
(LT) [2, 3, 6, 10, 11].
Orpha number: ORPHA64743Epidemiology
Although INCPH has a worldwide distribution, it is par-
ticularly prevalent in Asia [4, 12, 13]. It is more frequent
in socioeconomically disadvantaged individuals. Im-
provements in hygiene and living standards may explains article distributed under the terms of the Creative Commons Attribution
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last decades, and the low prevalence of the disease in
Western countries [7, 9, 14, 15]. Gender and age disparities
have also been reported [4, 15]. In Western populations,
median age at diagnosis is 40 years, with predominance in
male gender. Conversely, Asian patients tend to be diag-
nosed at a younger age. In summary, differences in socio-
economic status, living conditions, pathogen exposure and
ethnicity may play a role in INCPH development.
Etiology and pathophysiology
Etiology
The etiology of INCPH is unknown [1, 4, 9, 14, 16].
Strikingly, small series and case studies show its associ-
ation with an array of rare disorders; whether these asso-
ciations are more than fortuitous remains unclear.
Roughly, the potential mechanisms involved in INCPH
pathogenesis can be classified in five main categories:
immunological disorders, chronic infections, exposure to
medications or toxins, genetic disorders and prothrom-
botic conditions (Table 1). A combination of these
factors is also very likely. Associated conditions in 4 re-
cently reported European series are described in Table 2
[2, 6, 10, 11, 16].
Immunological disorders
In Western countries, INCPH is frequently associated
with immunological disorders [3, 5, 7, 17, 18]. In patients
with systemic sclerosis, enhanced fibrogenesis seems to
have a major pathogenic role [8]. Also, in patients withTable 1 Associated disorders of idiopathic non-cirrhotic portal
hypertension
Immunological disorders Common variable immunodeficiency
syndrome [22, 54]
Connective tissue diseases [55]
Crohn’s disease [26, 27]
Solid organ transplant [56, 57]
Infections Bacterial intestinal infections [21]
Human immunodeficiency virus (HIV)
infection [2, 9, 14, 22]
Medications and toxins Thiopurine derivatives (didanosine,
azathioprine, cis-thioguanine) [27, 58]
Arsenicals [28]
Vitamin A [59]
Genetic disorders Adams-Olivier syndrome [32]
Turner syndrome [30]
Phosphomannose isomerase deficiency [60]
Familial cases [31, 61]
Prothrombotic conditions Inherited thrombophilias [2, 6, 10, 11, 62]
Myeloproliferative neoplasm [2, 6, 10, 11, 62]
Antiphospholipid syndrome [2, 6, 10, 11, 62]systemic lupus erythematosus, immunoglobulin interfer-
ence with prostacyclin formation has been found to in-
crease microthrombosis vulnerability [19]. In patients with
celiac disease, an elevation of IgA anticardiolipin anti-
bodies could be responsible for the obliteration of small
vessels [1–7]. Interestingly, 70 % of patients with primary
hypogammaglobulinemia have histological features of
INCPH [1, 3, 7–9, 20].Chronic infections
Data indicate that intestinal infection with E. coli might
cause recurrent septic embolization and subsequent ob-
struction of small portal veins, a probable trigger of
INCPH. The high prevalence of INCPH in low socioeco-
nomic areas with a high rate of abdominal infections in
early childhood lends credit to this theory [1, 2, 4, 5]. In
addition, experimental studies demonstrate how E. coli
injection into the portal vein results in the development
clinical and histological characteristics of INCPH [2, 3,
6, 10, 11, 21].
In Western countries, INCPH has been reported in-
creasingly in patients with human immunodeficiency
virus (HIV) infection [4, 9, 12–14, 17, 22–24]. Prolonged
monotherapy or short-term combination treatment with
didanosine and stavudine are independent risk factors
for the development of this disorder, suggesting a poten-
tial role for mitochondrial toxicity in the development
of INCPH [7, 9, 14, 15, 17, 22]. A recent multicenter
study demonstrated a genetic predisposition to develop
INCPH in HIV infected patients chronically exposed to
didanosine [4, 15, 25]. Despite these data, it is difficult
to assign a definitive etiopathogenic role of didanosine,
as the drug has been widely used for the treatment of
HIV in the past. Alternatively, a high prevalence of pre-
existing hypercoagulability, mainly due to protein S defi-
ciency, possibly leading to vascular obstruction, has also
been reported in patients with HIV-related INCPH [1, 4,
9, 14, 16]. Hence, additional data will be needed to de-
fine a causal role of didanosine exposure and HIV-
associated INCPH [2, 6, 7, 10, 11, 16, 17].Exposure to medication and toxins
Besides didanosine, exposure to other medications and
chemicals has been reported to be associated with
INCPH. Azathioprine, 6-thioguanine and arsenic as
Fowler’s solution are the most frequently reported drugs
linked with this disorder [3, 5, 7, 17, 26–28]. Although it
is tempting to blame drug intake and chemical exposure
as primary etiological factors, only a very small propor-
tion of the patients treated with the above mentioned
drugs or exposed to these chemicals develop clinical or
histological signs of INCPH. Clearly, additional factors
may play a pathogenic role in these patients.
Table 2 Associated conditions in 4 recently reported series of European patients with idiopathic non-cirrhotic portal hypertension
Reference Hillaire et al. [6] Cazals-Hatem et al. [11] Schouten et al. [10] Siramolpiwat et al. [2]
Prothrombotic disorder 6 PS deficiency 3 PS deficiency 3 PS deficiency 1 PS deficiency
2 PC deficiency 3 PC deficiency 3 PC deficiency 2 FII Leiden
2 MTHFR mutation 1 MTHFR mutation 1 FV Leiden
3 FII Leiden 2 FV Leiden
Haematological malignancy 1 0 4 5
Myeloproliferative neoplasm 6 10 3 0
Chronic HIV infection 0 0 5 15
Autoimmune disorder 3 10 1 9
Crohn’s disease 0 0 3 0
Genetic disorder 0 0 4 0
Solid organ malignancy 0 0 1 0
Azathioprine treatment 0 0 8 0
Arsenicals - 0 4 0
No associated conditions 12 31 26 30
Incomplete evaluation 2 - - 9
Totala 28 59 62 69
FII factor II, FV Leiden factor V Leiden, HIV human immunodeficiency virus, MTHFR metilentetrahydorfolate reductase, PC protein C, PS protein S
(a): Some patients have more than one associated condition
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Reports on familial aggregation of INCPH and presence
of its key histologic features in congenital disorders (e.g.
Adams-Oliver syndrome, Turner disease) indicate a pos-
sible genetic component in INCPH [18, 29–33]. There is
evidence of an association between HLA-DR3 and
INCPH, what also supports an immunogenetic basis of
this disorder [8, 31].Prothrombotic conditions
Thrombophilia seems invariable behind some clinical
and histologic features of patients with INCPH. There
are different pieces of evidence suggestive of this includ-
ing the high prevalence (30-50 %) of pre-existing hyper-
coagulability commonly reported in INCPH patients [2,
6, 10, 11, 19, 34]. Also, these patients tend to have a
relatively high incidence of portal vein thrombosis [2, 6,
10, 11]. In addition, certain pathologic features in liver
specimens of INCPH patients support a dominant role
of thrombophilia in the development of INCPH [6, 11,
35, 36]. Presence of obliterative portal venopathy (i.e. lu-
minal narrowing or obliteration of small portal venous
branches accompanied by dense deposits of elastic fi-
bers) in liver specimens of INCPH patients is highly
suggestive of previous thrombotic episodes. Further-
more, the majority of liver explants from transplanted
INCPH patients demonstrate organized old thrombi in
the large portal vein branches [37, 38].Pathogenesis
A dual theory, implicating both intrahepatic vascular ob-
struction and increased splanchnic blood flow, has been
suggested to explain portal hypertension in INCPH pa-
tients [1, 6, 39]. An increased intrahepatic resistance likely
results from the obstructed intrahepatic vessels (i.e. phle-
bosclerosis) and distorted intrahepatic angioarchitecture
(i.e. nodular regeneration). The mechanisms responsible
for the obliteration of portal venules remain unknown.
Several hypotheses have been proposed [1, 34, 39], includ-
ing aberrant coagulation activation or thrombosis, ac-
quired or inherited disorders of vascular remodeling, and
endothelial injury from immune cells [40]. Similar to
cirrhosis, the imbalance of different vasoactive media-
tors causing intrahepatic vasoconstriction could also be
considered. Additionally to the increased intrahepatic
resistance, a portal venous overflow secondary to spleno-
megaly has been linked to the development of portal
hypertension in INCPH patients [41, 42]. Overproduction
of nitric oxide, released in the sinus lining spleen cells,
could also justify the dilatation of splenic sinuses and sub-
sequent massive splenomegaly frequently found in INCPH
patients [1, 43].Clinical manifestations
Complications related to portal hypertension dominate
the signs and symptoms present in patients with INCPH
[1, 2, 34, 39]. The liver function is usually preserved.
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Unlike cirrhotic patients, prognosis of variceal bleeding
in INCPH is usually good due to the preserved liver
function. In those patients without variceal bleeding at
diagnosis, over 75 % had varices at the initial endoscopy
[2, 34]. A recent study has shown that the 1-year prob-
ability of developing small and large varices was 10 %
and 13 %, respectively; this is similar to what is de-
scribed in cirrhotic patients [2]. This study also showed
that in patients with large varices, the 1-year probability
of first bleeding episode despite primary prophylaxis was
9 %. In addition, the 1-year probability of re-bleeding
despite combined secondary prophylaxis (i.e. beta-
blockers and endoscopic band ligation) was 22 % [2].
Ascites is reported in up to 50 % of cases, and it usually
develops in the context of precipitating factors such as
variceal bleeding or infections. Generally, it is easily con-
trolled with low dose of diuretics and resolution of the
trigger [1, 10]. Hepatic encephalopathy is a rare complica-
tion and it is also related to precipitating factors. There
are anecdotic reports of hepatopulmonary syndrome, por-
topulmonary hypertension and hepatocellular carcinoma.
Over 95 % of patients have splenomegaly and it can cause
left upper quadrant’s abdominal pain.
Portal vein thrombosis (PVT) is also common, with a
reported prevalence that ranges from 13-46 % [2, 6, 10].
A recent study found a 9 % annual probability of devel-
oping PVT. HIV infection and the presence of variceal
bleeding at diagnosis have been described as factors in-
dependently associated with a high risk of developing
PVT [2, 7]. Remarkably, most patients are asymptomatic
at the time of PVT diagnosis. Therefore, it may be useful
to screen for the presence of PVT in INCPH patients. It
is unclear, however, the optimal frequency or best im-
aging modality in this context.
Diagnosis
There is a lack of a specific positive test that leads to an
INCPH diagnosis. It is based on clinical criteria and the
formal exclusion of other causes of PH; this represents a
clinical challenge, even in experienced liver units. Con-
sequently, INCPH is frequently unrecognized, and in
many instances patients are misdiagnosed with liver cir-
rhosis [44, 45].
Criteria and differential diagnosis
The diagnosis of INCPH is a diagnosis of exclusion,
based on the following previously reported criteria [1]:
1) presence of unequivocal signs of portal hypertension
(e.g., gastroesophageal varices, ascites, and/or spleno-
megaly); 2) absence of cirrhosis, advanced fibrosis or
other causes of chronic liver diseases that can cause PH
by appropriate serological, biochemical tests and liver
biopsy and; 3) absence of thrombosis of the hepaticveins or of the portal vein at imaging studies performed
at diagnosis.
Therefore, the current diagnostic work up for INCPH
should include: 1) detailed medical history to investigate
concomitant diseases and exposure to drugs, medica-
tions or toxins, 2) liver imaging to evaluate the patency
of the splanchnic venous axis, 3) laboratory tests to rule
out other causes of liver diseases and/or PH and 4) a
mandatory liver biopsy to discard cirrhosis and other
causes of chronic liver disease with or without PH. As a
result, a diagnosis of INCPH can only be made upon the
exclusion of liver cirrhosis, portal vein thrombosis,
Budd-Chiari syndrome, chronic liver diseases causing
noncirrhotic portal hypertension (e.g. chronic viral hepa-
titis, primary biliary cirrhosis, non-alcoholic steatohepa-
titis, alcoholic steatohepatitis and autoimmune hepatitis)
and conditions causing portal hypertension (congenital
liver fibrosis, sarcoidosis and schistomiasis).
Liver function tests
Liver function tests are usually within normal range; jaun-
dice is rarely seen at diagnosis. Transient impairments in
liver function may occur in the context of variceal bleeding
or infection. Anemia, leukopenia, and thrombocytopenia
are common due to hypersplenism.
Imaging
Comprehensive liver imaging is required before INCPH
can be confidently diagnosed. The goals of liver imaging
are twofold: 1) to determine the presence of radiological
signs of PH such as splenomegaly, collaterals or ascites,
and 2) to evaluate the patency of the hepatic veins and
the porto-spleno-mesenteric venous axis. Of note, most
patients also present radiological signs of chronic liver
disease (i.e. liver surface nodularity) despite the lack of
histologic cirrhosis [45]. Doppler ultrasound in addition
to CT angiography or MRI angiography is the recom-
mended strategy.
Liver biopsy / liver pathology
The morphological features associated with INCPH can
be sometimes subtle, what makes pivotal an adequate
histological evaluation by expert liver pathologists. It is
essential to systematically assess the different anatomical
structures in the liver, including their size, topography
and morphology. At the portal tracts, presence of a bile
duct, a branch of the hepatic artery and of a normally
sized portal vein needs to be determined. Hypoplastic or
minute portal tracts, with a lumen of the bile duct or ar-
tery smaller than the surrounding hepatocytes are typical
of INCPH (Fig. 1) [35]. These are thought to be portal
tract remnants, resulting from resorption of normal por-
tal tract collagen [46]. Portal sclerosis or hepatoportal
sclerosis is also a common feature. It consists of fibrous
Fig. 1 a Paraportal shunting vessel (arrow), herniating into the liver parenchyma. The adjacent portal tract has a bile duct (*), hepatic artery (#)
and portal vein (+); PAS staining, 20x. b Phlebosclerosis. In a fibrotic portal tract (arrow), a bile duct (*), hepatic artery (#) and arterialised portal
vein (+) are present; haematoxylin and eosin, 20x. c Hypoplastic portal tract in which the lumen of the bile duct (*) is smaller than the diameter
of the surrounding hepatocytes; PAS-amylase staining, 40 x. d Nodular regenerative hyperplasia (NRH) with central hyperplasia and an atrophic
rim (arrow) in the absence of fibrosis; reticulin staining, 10x
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portal vein thrombosis and consequent organization, ei-
ther from the larger portal vein branches or in the con-
text of local portal tract pathology. Some authors use
the term obliterative portal venopathy for this entity.
Other findings in the context of INCPH in the (peri)por-
tal area include dilated portal veins, abnormal spacing
between portal tracts and veins, an increased number of
vascular structures in the portal tracts, arterialization of
the wall of portal veins and the presence of paraportal
shunting vessels and/or herniating in the liver paren-
chyma [38, 47, 48].
In the liver parenchyma, abnormalities that may be
seen in the context of INCPH include sinusoidal dilata-
tion, congestion and pericellular fibrosis, aberrant hep-
atic vessels and dilatation of the central vein with or
without perivenular fibrosis. The lumen of the centralveins can be (partially) occluded associated with differ-
ent toxic agents. A regenerative, compensatory response
can be the result of a heterogeneous blood flow in the
presence of circulatory abnormalities at different levels
of the microcirculation. This might lead to nodular re-
generative hyperplasia, showing micronodular trans-
formation, with central hyperplasia and an atrophic rim
in the absence of fibrosis [48, 49]. Pathologists should
become familiar with these features, in order to suggest
or support the clinical diagnosis of INCPH in patients
with non-cirrhotic portal hypertension.
Other investigations
INCPH is an intrahepatic presinusoidal cause of PH
[44, 50]. Hepatic venous pressure gradient (HVPG) is
normal (≤5 mmHg) or slightly increased (5-10 mmHg)
but below the previously described cut-off for clinically
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HVPG>10 mmHg) [37, 51]. Also, liver stiffness value on
transient elastography (Fibroscan®) is lower than the de-
scribed cut-off values for diagnosing cirrhosis, varices
and CSPH [2, 7, 51]. Thus, lower values for HVPG and
liver stiffness than those described for cirrhosis and
CSPH can be helpful by ruling out cirrhosis in a patient
with signs of PH.
Treatment
Management of portal hypertension
Data on management and prophylaxis of variceal bleed-
ing in INCPH patients are scarce with a remarkable lack
of randomized controlled trials. There are no specific
guidelines for the management of PH in patients with
INCPH. Nevertheless, expert opinion recommends fol-
lowing the guidelines of prophylaxis and management of
PH in cirrhotic patients [1]. A recent cohort study re-
ported good long-term outcome by applying a manage-
ment strategy based on current guidelines for cirrhotic
variceal bleeding [2].
Briefly, primary and secondary prevention of variceal
bleeding includes the use of non-selective beta-blockers
and endoscopic variceal ligation. Trans-jugular intrahepa-
tic portosystemic shunting (TIPSS) is an effective alterna-
tive in patients who fail to respond to medical and
endoscopic therapy. Management of acute variceal bleed-
ing includes early pharmacological treatment with vaso-
active drugs, early endoscopic control of bleeding, careful
blood product replacement, and prophylactic antibiotics
[52]. Guidelines also recommend withdrawing any drug
potentially associated with INCPH (e.g. azathioprine) and
treating any associated medical conditions [52].
Liver transplant
Even though INCPH patients usually have well preserved
liver function, and PH related complications are success-
fully controlled, some patients may require a LT. Some of
the reported indications for LT include unmanageable PH,
progressive liver failure, chronic hepatic encephalopathy,
hepatopulmonary syndrome and hepatocellular carcin-
oma. Post-LT outcomes of INCPH patients are good and
the disease tends not to recur. However, data on this issue
are limited and mostly based on small cohorts [1, 45].
Management of PVT
The use of anticoagulation in the management of PVT
in INCPH is controversial, mainly due to the lack of
prospective data. Nevertheless, we believe that anticoagu-
lation therapy must be considered in patients with under-
lying prothrombotic conditions and in patients who
develop PVT. A recent retrospective series described 15
patients with INCPH and PVT that were treated with an-
ticoagulants. At the end of follow-up, 54 % of patientsachieved some degree of recanalization [2]. Regarding
anticoagulation in these patients, some issues that need to
be addressed: 1) which are the subgroup of PVT patients
that benefit from anticoagulation, 2) which is the best
anticoagulantion modality (low molecular weight heparins
vs vitamin-K antagonist vs new oral anticoagulants), 3)
which is the optimal duration of anticoagulation and 4)
which are the early predictors of response. Another im-
portant point is whether anticoagulation may have a
role in the prevention of PVT. Based on the high preva-
lence of thrombophilia, the frequent presence of throm-
bosis of small intrahepatic and main portal veins in
INCPH, it would be even more important to determine
whether anticoagulation could play a role to prevent
disease progression.
Prognosis
Very few studies have evaluated the long-term prognosis
of INCPH patients. Overall, prognosis is generally better
than in patients with cirrhosis and a similar degree of
portal hypertension. As mentioned above, this may be
due to the fact that most INCPH patients have well pre-
served liver function. However, a small subgroup of pa-
tients will develop liver failure and will require LT. Two
recent European cohort studies evaluated prognosis of
INCPH [2, 10, 32]. The Dutch study reported low overall
and LT-free survival, 78 % and 72 % at 5 years, respect-
ively. However, it should be noted that only 13 % of pa-
tients died from liver-related causes. Conversely, the
Spanish cohort reported 86 % of LT-free survival at
5 years. Interestingly, ascites was identified as a poor
prognostic factor in both studies. The presence of a con-
comitant severe disorder such as an immunological dis-
ease or malignancy was also identified as a poor
prognostic factor in the Spanish study.
Conclusions and future perspectives
Over the last decade, numerous efforts have tried to
clarify different aspects of INCPH. First, the nomencla-
ture concerning this clinical disorder has been ambigu-
ous and highly depended on histological features. To
facilitate future studies and subsequently enhance our
understanding of the disease, common terminology and
diagnostic criteria have been developed [1]. Regarding
pathophysiology, some genetic traits have been identified
in HIV-associated INCPH [25]. Furthermore, cohort
studies performed in Europe provided new insights into
the natural course and prognosis of these patients [2, 10,
11]. Despite these improvements, several uncertainties
related to its pathogenesis should be further addressed.
Large multicenter studies studying INCPH prevalence,
associated disorders, natural course and prognosis are
an unmet need. The diagnosis of INCPH still relies on
clinical and histologic elements; future research should
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ease. Furthermore, no randomized controlled trials have
been yet performed. Currently, treatment of INCPH pa-
tients is based on the prevention of complications of
portal hypertension as per guidelines for patients with
liver cirrhosis. These treatment modalities have not been
systematically evaluated in INCPH. So far, no treatment
able to modify the course of the disease or to prevent
complications has been tested in INCPH. Considering
the role of thrombophilia in the pathophysiology of this
disorder, it seems that anticoagulation therapy could
prevent the progression of INCPH, but prospective con-
trolled data are still needed. Limited available data in
INCPH patients show no increased risk of serious bleed-
ing [2, 11, 53] and a significant rate of portal vein recanali-
zation in patients with associated portal vein thrombosis
[2]. Furthermore, evidence generated in other vascular
liver diseases such as PVT or Budd-Chiari syndrome dem-
onstrate that prolonged anticoagulation improves out-
comes without increasing significantly the risk of serious
bleeding. Hopefully, future randomized trials will provide
new tools to tackle this orphan disease and improve our
understanding of its complex pathophysiology.Nomenclature
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